Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Erythropoietin (EPO) hyporesponsiveness continues to challenge anemia management in patients with chronic kidney disease (CKD), despite adherence to KDIGO-recommended dosing strategies. Persistent anemia in such cases often warrants exploration of alternative therapeutic options. Desidustat, an oral hypoxia-inducible factor–prolyl hydroxylase inhibitor (HIF-PHI), stimulates endogenous erythropoietin production and enhances iron utilization. This study evaluated the hematologic response and biochemical safety of Desidustat in EPO-hyporesponsive CKD patients undergoing dialysis.
A total of 32 patients (13 females, 19 males; mean age 44.34 ± 8.64 years) who remained anemic despite receiving high-dose EPO therapy (170 IU/kg/week) for 2 months were enrolled. All met KDIGO criteria for EPO hyporesponsiveness. EPO was discontinued, and all patients were initiated on Desidustat oral therapy. Hemoglobin (Hb), renal, and biochemical parameters were assessed at baseline, 1 month, and 3 months. Statistical comparisons were performed using paired t-tests.
At baseline, mean Hb was 7.07 ± 0.52 g/dL. Following switch to Desidustat:
Hb at 1 month: 7.83 ± 0.63 g/dL (Δ = +0.76 g/dL; +10.7%, p = 0.00023)
Hb at 3 months: 8.55 ± 0.71 g/dL (Δ = +1.48 g/dL; +20.9%, p = 0.00052)
Despite previous high-dose EPO exposure with suboptimal response, patients demonstrated a clinically and statistically significant rise in Hb within 3 months of Desidustat therapy.
Metabolic parameters remained stable throughout follow-up:
Creatinine: 3.25 ± 1.00 mg/dL
Calcium: 8.92 ± 0.36 mg/dL
Phosphate: 4.62 ± 0.60 mg/dL
ALP: 118.8 ± 33.97 U/L
Na/K: 138.5 ± 2.88 / 4.57 ± 0.39 mmol/L
Transferrin Saturation: 27.47 ± 6.83%
Ferritin: 288.8 ± 99.24 ng/mL
No significant derangements or safety concerns were observed, suggesting a favorable tolerability profile.
Desidustat demonstrated robust hemoglobin improvement in patients previously unresponsive to high-dose EPO therapy, meeting KDIGO anemia management targets within 3 months. The stable biochemical profile supports its safety and efficacy as an oral alternative to injectable erythropoiesis-stimulating agents in this difficult-to-treat population.
